nodes	percent_of_prediction	percent_of_DWPC	metapath
Niflumic Acid—PLA2G4A—Epirubicin—sarcoma	0.671	0.778	CbGbCtD
Niflumic Acid—PTGS2—Etoposide—sarcoma	0.104	0.12	CbGbCtD
Niflumic Acid—PTGS1—Etoposide—sarcoma	0.0875	0.102	CbGbCtD
Niflumic Acid—CLCNKA—testis—sarcoma	0.00574	0.0517	CbGeAlD
Niflumic Acid—CLCNKA—liver—sarcoma	0.00543	0.0488	CbGeAlD
Niflumic Acid—PTGS2—periosteum—sarcoma	0.00526	0.0473	CbGeAlD
Niflumic Acid—PTGS2—leg—sarcoma	0.00419	0.0377	CbGeAlD
Niflumic Acid—PLA2G1B—hematopoietic system—sarcoma	0.00414	0.0373	CbGeAlD
Niflumic Acid—SLC16A7—myometrium—sarcoma	0.00406	0.0365	CbGeAlD
Niflumic Acid—PLA2G1B—connective tissue—sarcoma	0.00399	0.0359	CbGeAlD
Niflumic Acid—PTGS2—hindlimb—sarcoma	0.00375	0.0337	CbGeAlD
Niflumic Acid—PTGS2—cartilage tissue—sarcoma	0.00369	0.0332	CbGeAlD
Niflumic Acid—PTGS2—appendage—sarcoma	0.00321	0.0289	CbGeAlD
Niflumic Acid—PLA2G4A—myometrium—sarcoma	0.00294	0.0264	CbGeAlD
Niflumic Acid—PLA2G4A—seminal vesicle—sarcoma	0.00265	0.0239	CbGeAlD
Niflumic Acid—SLC16A7—cardiac atrium—sarcoma	0.00265	0.0238	CbGeAlD
Niflumic Acid—SLC16A7—uterus—sarcoma	0.00264	0.0237	CbGeAlD
Niflumic Acid—PLA2G4A—hematopoietic system—sarcoma	0.00252	0.0227	CbGeAlD
Niflumic Acid—PLA2G4A—connective tissue—sarcoma	0.00243	0.0218	CbGeAlD
Niflumic Acid—SLC16A7—tendon—sarcoma	0.00231	0.0208	CbGeAlD
Niflumic Acid—PLA2G1B—testis—sarcoma	0.00227	0.0204	CbGeAlD
Niflumic Acid—PLA2G4A—smooth muscle tissue—sarcoma	0.00222	0.02	CbGeAlD
Niflumic Acid—SLC16A1—hematopoietic system—sarcoma	0.00222	0.02	CbGeAlD
Niflumic Acid—PTGS1—endothelium—sarcoma	0.00203	0.0182	CbGeAlD
Niflumic Acid—UGT1A9—liver—sarcoma	0.00196	0.0177	CbGeAlD
Niflumic Acid—PTGS2—endothelium—sarcoma	0.00194	0.0174	CbGeAlD
Niflumic Acid—SLC16A7—testis—sarcoma	0.00191	0.0172	CbGeAlD
Niflumic Acid—SLC16A7—liver—sarcoma	0.00181	0.0163	CbGeAlD
Niflumic Acid—SLC16A1—cardiac atrium—sarcoma	0.00169	0.0152	CbGeAlD
Niflumic Acid—SLC16A1—uterus—sarcoma	0.00168	0.0151	CbGeAlD
Niflumic Acid—PLA2G4A—tendon—sarcoma	0.00167	0.015	CbGeAlD
Niflumic Acid—PLA2G4A—bone marrow—sarcoma	0.00162	0.0145	CbGeAlD
Niflumic Acid—SLC16A1—tendon—sarcoma	0.00147	0.0132	CbGeAlD
Niflumic Acid—SLC16A7—lymph node—sarcoma	0.00139	0.0125	CbGeAlD
Niflumic Acid—PLA2G4A—testis—sarcoma	0.00138	0.0124	CbGeAlD
Niflumic Acid—SLC16A1—testis—sarcoma	0.00122	0.0109	CbGeAlD
Niflumic Acid—SLC16A1—liver—sarcoma	0.00115	0.0104	CbGeAlD
Niflumic Acid—PTGS2—myometrium—sarcoma	0.00111	0.00998	CbGeAlD
Niflumic Acid—PTGS2—embryo—sarcoma	0.00107	0.00959	CbGeAlD
Niflumic Acid—PTGS1—seminal vesicle—sarcoma	0.00105	0.00943	CbGeAlD
Niflumic Acid—PLA2G4A—lymph node—sarcoma	0.001	0.00901	CbGeAlD
Niflumic Acid—PTGS2—seminal vesicle—sarcoma	0.001	0.00901	CbGeAlD
Niflumic Acid—PTGS1—hematopoietic system—sarcoma	0.000996	0.00896	CbGeAlD
Niflumic Acid—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—PLCG1—sarcoma	0.000995	0.037	CbGpPWpGaD
Niflumic Acid—PTGS1—connective tissue—sarcoma	0.000959	0.00863	CbGeAlD
Niflumic Acid—PTGS2—hematopoietic system—sarcoma	0.000952	0.00857	CbGeAlD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.000928	0.0345	CbGpPWpGaD
Niflumic Acid—PTGS2—connective tissue—sarcoma	0.000917	0.00825	CbGeAlD
Niflumic Acid—SLC16A1—lymph node—sarcoma	0.000882	0.00794	CbGeAlD
Niflumic Acid—PTGS1—smooth muscle tissue—sarcoma	0.000878	0.00789	CbGeAlD
Niflumic Acid—PTGS1—skin of body—sarcoma	0.000866	0.00779	CbGeAlD
Niflumic Acid—PTGS2—smooth muscle tissue—sarcoma	0.000839	0.00754	CbGeAlD
Niflumic Acid—PTGS2—skin of body—sarcoma	0.000828	0.00745	CbGeAlD
Niflumic Acid—PTGS1—cardiac atrium—sarcoma	0.000757	0.0068	CbGeAlD
Niflumic Acid—PTGS1—uterus—sarcoma	0.000753	0.00677	CbGeAlD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—EZR—sarcoma	0.000737	0.0274	CbGpPWpGaD
Niflumic Acid—PTGS2—uterus—sarcoma	0.000719	0.00647	CbGeAlD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—TEK—sarcoma	0.000685	0.0255	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.000671	0.0249	CbGpPWpGaD
Niflumic Acid—PTGS2—lymphoid tissue—sarcoma	0.000671	0.00603	CbGeAlD
Niflumic Acid—PTGS1—tendon—sarcoma	0.000659	0.00593	CbGeAlD
Niflumic Acid—PLA2G4A—PDGF Pathway—PLCG1—sarcoma	0.000647	0.0241	CbGpPWpGaD
Niflumic Acid—PTGS2—tendon—sarcoma	0.00063	0.00567	CbGeAlD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—ANGPT2—sarcoma	0.000627	0.0233	CbGpPWpGaD
Niflumic Acid—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.000617	0.0229	CbGpPWpGaD
Niflumic Acid—PTGS2—bone marrow—sarcoma	0.000611	0.00549	CbGeAlD
Niflumic Acid—PTGS1—testis—sarcoma	0.000546	0.00491	CbGeAlD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.000497	0.0185	CbGpPWpGaD
Niflumic Acid—PTGS2—liver—sarcoma	0.000493	0.00444	CbGeAlD
Niflumic Acid—PLA2G4A—PDGF Pathway—PDGFRB—sarcoma	0.000459	0.017	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—PLCG1—sarcoma	0.000453	0.0168	CbGpPWpGaD
Niflumic Acid—UGT1A9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000446	0.0166	CbGpPWpGaD
Niflumic Acid—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.000437	0.0163	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Ca-dependent events—CREB1—sarcoma	0.000411	0.0153	CbGpPWpGaD
Niflumic Acid—PTGS1—lymph node—sarcoma	0.000396	0.00356	CbGeAlD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—PLCG1—sarcoma	0.000395	0.0147	CbGpPWpGaD
Niflumic Acid—PTGS2—lymph node—sarcoma	0.000378	0.0034	CbGeAlD
Niflumic Acid—PLA2G4A—p38 MAPK Signaling Pathway—CREB1—sarcoma	0.000372	0.0138	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	0.000368	0.0137	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000363	0.0135	CbGpPWpGaD
Niflumic Acid—PTGS2—S1P1 pathway—KDR—sarcoma	0.000362	0.0135	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00036	0.0134	CbGpPWpGaD
Niflumic Acid—PLA2G4A—ADP signalling through P2Y purinoceptor 1—SRC—sarcoma	0.000307	0.0114	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PLC beta mediated events—CREB1—sarcoma	0.000303	0.0112	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—FOXO1—sarcoma	0.000302	0.0112	CbGpPWpGaD
Niflumic Acid—PLA2G4A—G-protein mediated events—CREB1—sarcoma	0.000297	0.011	CbGpPWpGaD
Niflumic Acid—UGT1A9—PPAR Alpha Pathway—CCND1—sarcoma	0.000275	0.0102	CbGpPWpGaD
Niflumic Acid—PTGS1—Selenium Micronutrient Network—HBA1—sarcoma	0.000267	0.00993	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.000266	0.00987	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.000266	0.00987	CbGpPWpGaD
Niflumic Acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.000262	0.00974	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000261	0.00971	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signal amplification—SRC—sarcoma	0.000258	0.0096	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—PLCG1—sarcoma	0.000255	0.00948	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGF Pathway—JUN—sarcoma	0.00024	0.00891	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000239	0.00887	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	0.000232	0.00864	CbGpPWpGaD
Niflumic Acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.000229	0.00851	CbGpPWpGaD
Niflumic Acid—UGT1A9—PPAR Alpha Pathway—MYC—sarcoma	0.000221	0.00821	CbGpPWpGaD
Niflumic Acid—PLA2G4A—p38 MAPK Signaling Pathway—MYC—sarcoma	0.000215	0.00799	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGF Pathway—SRC—sarcoma	0.000215	0.00799	CbGpPWpGaD
Niflumic Acid—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.000212	0.00788	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.000206	0.00765	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—MMP2—sarcoma	0.000204	0.00757	CbGpPWpGaD
Niflumic Acid—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.0002	0.00742	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000195	0.00724	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TEK—sarcoma	0.000186	0.00691	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Opioid Signalling—CREB1—sarcoma	0.000186	0.0069	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—PDGFRB—sarcoma	0.000181	0.00671	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000179	0.00665	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000174	0.00647	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000172	0.00641	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—ANGPT2—sarcoma	0.00017	0.00632	CbGpPWpGaD
Niflumic Acid—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—sarcoma	0.000169	0.00628	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—sarcoma	0.000168	0.00623	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.000167	0.00622	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—JUN—sarcoma	0.000163	0.00607	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000163	0.00605	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—JUN—sarcoma	0.000157	0.00585	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000156	0.0058	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGF Pathway—HRAS—sarcoma	0.000151	0.00562	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—SRC—sarcoma	0.000146	0.00544	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TEK—sarcoma	0.000144	0.00537	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—SRC—sarcoma	0.000141	0.00525	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.00014	0.00521	CbGpPWpGaD
Niflumic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000137	0.00509	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—VEGFC—sarcoma	0.000136	0.00507	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—ANGPT2—sarcoma	0.000132	0.00491	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—SRC—sarcoma	0.000131	0.00488	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000128	0.00476	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000127	0.00471	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—NRAS—sarcoma	0.000126	0.00469	CbGpPWpGaD
Niflumic Acid—PLA2G4A—AGE/RAGE pathway—EGFR—sarcoma	0.000124	0.0046	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—KRAS—sarcoma	0.000109	0.00404	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000108	0.00403	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—PLCG1—sarcoma	0.000107	0.00398	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—VEGFC—sarcoma	0.000106	0.00394	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—sarcoma	0.000106	0.00393	CbGpPWpGaD
Niflumic Acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000105	0.00392	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Endothelins—HRAS—sarcoma	0.000103	0.00383	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000102	0.00378	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000101	0.00375	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	9.84e-05	0.00366	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	9.72e-05	0.00361	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—JUN—sarcoma	9.44e-05	0.00351	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	9.35e-05	0.00348	CbGpPWpGaD
Niflumic Acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	9.25e-05	0.00344	CbGpPWpGaD
Niflumic Acid—SLC16A1—Cell surface interactions at the vascular wall—HRAS—sarcoma	9.23e-05	0.00343	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	9.05e-05	0.00336	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	8.85e-05	0.00329	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—ENO2—sarcoma	8.75e-05	0.00325	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—HBA1—sarcoma	8.69e-05	0.00323	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—SRC—sarcoma	8.47e-05	0.00315	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	8.36e-05	0.00311	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—PLCG1—sarcoma	8.33e-05	0.0031	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—NRAS—sarcoma	8.14e-05	0.00303	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	7.73e-05	0.00288	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—MYC—sarcoma	7.59e-05	0.00282	CbGpPWpGaD
Niflumic Acid—PLA2G1B—Metabolism—PLCG1—sarcoma	7.42e-05	0.00276	CbGpPWpGaD
Niflumic Acid—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	7.11e-05	0.00264	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—KRAS—sarcoma	7.01e-05	0.00261	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	6.97e-05	0.00259	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	6.79e-05	0.00252	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.74e-05	0.0025	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.72e-05	0.0025	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.67e-05	0.00248	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—IL2—sarcoma	6.15e-05	0.00229	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	6.03e-05	0.00224	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	6e-05	0.00223	CbGpPWpGaD
Niflumic Acid—PLA2G4A—PDGFR-beta signaling pathway—HRAS—sarcoma	5.96e-05	0.00221	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.87e-05	0.00218	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—MYC—sarcoma	5.59e-05	0.00208	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—IL2—sarcoma	5.45e-05	0.00203	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.4e-05	0.00201	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—SRC—sarcoma	5.37e-05	0.00199	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—CCND1—sarcoma	5.31e-05	0.00197	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.29e-05	0.00196	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—sarcoma	5.23e-05	0.00194	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	5.17e-05	0.00192	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—ENO2—sarcoma	5.12e-05	0.0019	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—HBA1—sarcoma	5.09e-05	0.00189	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	5.01e-05	0.00186	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.99e-05	0.00186	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CXCR4—sarcoma	4.59e-05	0.00171	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.44e-05	0.00165	CbGpPWpGaD
Niflumic Acid—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	4.39e-05	0.00163	CbGpPWpGaD
Niflumic Acid—SLC16A1—Metabolism—PLCG1—sarcoma	4.34e-05	0.00161	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TLE1—sarcoma	4.26e-05	0.00158	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—MYC—sarcoma	4.26e-05	0.00158	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—EGFR—sarcoma	4.17e-05	0.00155	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.15e-05	0.00154	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—IL2—sarcoma	4.08e-05	0.00152	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—ENO2—sarcoma	3.98e-05	0.00148	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—HBA1—sarcoma	3.96e-05	0.00147	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.61e-05	0.00134	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.6e-05	0.00134	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—VEGFC—sarcoma	3.59e-05	0.00134	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.58e-05	0.00133	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—SRC—sarcoma	3.56e-05	0.00132	CbGpPWpGaD
Niflumic Acid—PTGS2—Spinal Cord Injury—TP53—sarcoma	3.5e-05	0.0013	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—VEGFA—sarcoma	3.46e-05	0.00129	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—NRAS—sarcoma	3.42e-05	0.00127	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Metabolism—PLCG1—sarcoma	3.38e-05	0.00126	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—ENO2—sarcoma	3.3e-05	0.00123	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—HBA1—sarcoma	3.28e-05	0.00122	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—TLE1—sarcoma	3.26e-05	0.00121	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.23e-05	0.0012	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—IL2—sarcoma	3.17e-05	0.00118	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.15e-05	0.00117	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—KRAS—sarcoma	2.94e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—NPM1—sarcoma	2.94e-05	0.00109	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.9e-05	0.00108	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—FLT1—sarcoma	2.87e-05	0.00107	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.83e-05	0.00105	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PLCG1—sarcoma	2.82e-05	0.00105	CbGpPWpGaD
Niflumic Acid—UGT1A9—Metabolism—PLCG1—sarcoma	2.8e-05	0.00104	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—SRC—sarcoma	2.77e-05	0.00103	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CXCR4—sarcoma	2.71e-05	0.00101	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—VEGFA—sarcoma	2.69e-05	0.001	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—ENO2—sarcoma	2.69e-05	0.001	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—ATF1—sarcoma	2.68e-05	0.000998	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.68e-05	0.000995	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—HBA1—sarcoma	2.67e-05	0.000993	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—NRAS—sarcoma	2.66e-05	0.000989	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—TP53—sarcoma	2.62e-05	0.000973	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—ENO2—sarcoma	2.55e-05	0.000948	CbGpPWpGaD
Niflumic Acid—SLC16A1—Hemostasis—HRAS—sarcoma	2.5e-05	0.000931	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—CREB1—sarcoma	2.46e-05	0.000915	CbGpPWpGaD
Niflumic Acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.38e-05	0.000885	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—KRAS—sarcoma	2.29e-05	0.000851	CbGpPWpGaD
Niflumic Acid—PTGS1—Metabolism—PLCG1—sarcoma	2.28e-05	0.000848	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PLCG1—sarcoma	2.16e-05	0.000804	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—ENO2—sarcoma	2.13e-05	0.000794	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—HBA1—sarcoma	2.12e-05	0.000789	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IGF1R—sarcoma	2.11e-05	0.000783	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CXCR4—sarcoma	2.08e-05	0.000773	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—TP53—sarcoma	2.04e-05	0.000757	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—FOXO1—sarcoma	2e-05	0.000745	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PDGFRB—sarcoma	2e-05	0.000744	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—PDGFRA—sarcoma	1.97e-05	0.000732	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Hemostasis—HRAS—sarcoma	1.95e-05	0.000724	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—IL2—sarcoma	1.82e-05	0.000676	CbGpPWpGaD
Niflumic Acid—PTGS2—Metabolism—PLCG1—sarcoma	1.81e-05	0.000673	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KDR—sarcoma	1.66e-05	0.000616	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—FOXO1—sarcoma	1.53e-05	0.000571	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PDGFRB—sarcoma	1.53e-05	0.00057	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KIT—sarcoma	1.53e-05	0.000568	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—NRAS—sarcoma	1.53e-05	0.000568	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—PDGFRA—sarcoma	1.51e-05	0.000561	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CREB1—sarcoma	1.45e-05	0.00054	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—EGFR—sarcoma	1.39e-05	0.000517	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—KRAS—sarcoma	1.31e-05	0.000489	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MDM2—sarcoma	1.2e-05	0.000447	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—KIT—sarcoma	1.17e-05	0.000435	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling by GPCR—HRAS—sarcoma	1.12e-05	0.000415	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CREB1—sarcoma	1.11e-05	0.000414	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—IL2—sarcoma	1.07e-05	0.0004	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CCND1—sarcoma	1.05e-05	0.000389	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—JUN—sarcoma	1.05e-05	0.000389	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—CTNNB1—sarcoma	1.04e-05	0.000386	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—SRC—sarcoma	9.38e-06	0.000349	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MDM2—sarcoma	9.21e-06	0.000342	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—VEGFA—sarcoma	9.13e-06	0.00034	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—NRAS—sarcoma	9.02e-06	0.000335	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—MYC—sarcoma	8.4e-06	0.000312	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—EGFR—sarcoma	8.22e-06	0.000306	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—CTNNB1—sarcoma	7.94e-06	0.000295	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—KRAS—sarcoma	7.76e-06	0.000289	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—SRC—sarcoma	7.18e-06	0.000267	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—NRAS—sarcoma	6.91e-06	0.000257	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—TP53—sarcoma	6.9e-06	0.000257	CbGpPWpGaD
Niflumic Acid—PLA2G4A—Signaling Pathways—HRAS—sarcoma	6.6e-06	0.000245	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—MYC—sarcoma	6.43e-06	0.000239	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—EGFR—sarcoma	6.29e-06	0.000234	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—KRAS—sarcoma	5.95e-06	0.000221	CbGpPWpGaD
Niflumic Acid—PTGS2—Disease—HRAS—sarcoma	5.05e-06	0.000188	CbGpPWpGaD
